Entera Bio Ltd. (NASDAQ:ENTX) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Entera Bio Ltd. (NASDAQ:ENTX) have been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $9.60.

Several research analysts have weighed in on ENTX shares. UBS Group set a $9.00 price objective on shares of Entera Bio in a report on Friday, September 18th. Cantor Fitzgerald assumed coverage on shares of Entera Bio in a research report on Tuesday, September 22nd. They set an “overweight” rating on the stock. Wall Street Zen upgraded Entera Bio to a “sell” rating in a research note on Saturday, August 8th. Lifesci Capital initiated coverage on Entera Bio in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, October 15th.

Entera Bio Stock Performance

Shares of NASDAQ:ENTX opened at $2.92 on Monday. The business’s 50-day simple moving average is $2.89 and its 200 day simple moving average is $2.08. The company has a market cap of $507.85 million, a P/E ratio of -8.34 and a beta of 1.40. Entera Bio has a one year low of $0.91 and a one year high of $4.20.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Analysts predict that Entera Bio will post -0.40 earnings per share for the current year.

Institutional Trading of Entera Bio

An institutional investor recently raised its stake in Entera Bio stock. Renaissance Technologies LLC increased its holdings in Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 473,442 shares of the company’s stock after buying an additional 365,441 shares during the quarter. Renaissance Technologies LLC owned about 0.96% of Entera Bio worth $526,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.